0.96
price down icon0.41%   -0.004
after-market Handel nachbörslich: .90 -0.06 -6.25%
loading
Schlusskurs vom Vortag:
$0.964
Offen:
$1.01
24-Stunden-Volumen:
12.49M
Relative Volume:
2.82
Marktkapitalisierung:
$8.34M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.42M
KGV:
-0.0412
EPS:
-23.3189
Netto-Cashflow:
$-6.75M
1W Leistung:
-2.61%
1M Leistung:
+6.67%
6M Leistung:
-65.59%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$0.8502
$1.07
1-Wochen-Bereich:
Value
$0.8502
$1.09
52-Wochen-Spanne:
Value
$0.575
$23.13

Silexion Therapeutics Corp Stock (SLXN) Company Profile

Name
Firmenname
Silexion Therapeutics Corp
Name
Telefon
972-8-6286005
Name
Adresse
12 ABBA HILLEL ROAD, RAMAT GAN
Name
Mitarbeiter
14
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
SLXN's Discussions on Twitter

Vergleichen Sie SLXN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SLXN
Silexion Therapeutics Corp
0.96 8.57M 0 -16.42M -6.75M -23.32
Biotechnology icon
ONC
Beone Medicines Ltd Adr
246.68 25.81B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
447.09 111.46B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.30 40.37M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.39 64.44B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
77.49 6.19B 0 -153.72M -103.81M -2.00

Silexion Therapeutics Corp Aktie (SLXN) Neueste Nachrichten

pulisher
09:54 AM

Silexion reports breakthrough in KRAS-driven cancer therapy By Investing.com - Investing.com Nigeria

09:54 AM
pulisher
09:45 AM

Silexion reports breakthrough in KRAS-driven cancer therapy - Investing.com Australia

09:45 AM
pulisher
09:14 AM

Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers - The Manila Times

09:14 AM
pulisher
09:09 AM

Silexion Therapeutics Announces Groundbreaking Preclinical - GlobeNewswire

09:09 AM
pulisher
09:05 AM

Revolutionary Cancer Drug Shows 90% Inhibition Rate Against Pancreatic, Lung, and Colorectal Cancers in New Study - Stock Titan

09:05 AM
pulisher
May 26, 2025

Reviewing Silexion Therapeutics (NASDAQ:SLXN) & BioNTech (NASDAQ:BNTX) - Defense World

May 26, 2025
pulisher
May 23, 2025

Silexion Therapeutics Receives Nasdaq Delisting Notice - TipRanks

May 23, 2025
pulisher
May 22, 2025

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment - TradingView

May 22, 2025
pulisher
May 21, 2025

Silexion's SIL204 Completes Key Preclinical Studies In KRAS-Mutant Cancers - Nasdaq

May 21, 2025
pulisher
May 21, 2025

Silexion Therapeutics Completes Key Preclinical Studies Exploring Sil204's Potential Impact on Colorectal and Lung Cancer - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Silexion Completes Key Preclinical Studies for SIL204 - TipRanks

May 21, 2025
pulisher
May 21, 2025

Silexion Therapeutics Completes Key Preclinical Studies - GlobeNewswire

May 21, 2025
pulisher
May 21, 2025

Major Cancer Treatment Advance: Silexion's RNAi Drug Shows Promise Against 3 Deadly Cancers in $30B Market - Stock Titan

May 21, 2025
pulisher
May 13, 2025

Form 424B3 Silexion Therapeutics - StreetInsider

May 13, 2025
pulisher
May 13, 2025

Silexion Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Update - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Silexion Therapeutics Reports Q1 2025 Financial Results and Key Developments in RNAi Cancer Therapy - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

May 13, 2025
pulisher
May 02, 2025

SLXNSilexion Therapeutics Corp Latest Stock News & Market Updates - Stock Titan

May 02, 2025
pulisher
Apr 25, 2025

Is Silexion Therapeutics Corp (SLXN) positioned for future growth? - Sete News

Apr 25, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Partners with Catalent to Advance Revolutionary KRAS-Targeting Cancer Therapy - citybuzz -

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics partners with Catalent for cancer drug development By Investing.com - Investing.com South Africa

Apr 23, 2025
pulisher
Apr 23, 2025

SLXN’s price-to-sales ratio: Is it a good investment opportunity? - uspostnews.com

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Partners With Catalent To Advance SIL204 SiRNA Therapy For KRAS-Driven Cancers - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Partners with Catalent for SIL204 Development - TipRanks

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics partners with Catalent for cancer drug development - Investing.com Australia

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics enters collaboration with Catalent - TipRanks

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities - The Manila Times

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Enters Strategic Collaboration with Catalent to Advance SIL204 Development for KRAS-Driven Cancers - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Announces Collaboration with Global - GlobeNewswire

Apr 23, 2025
pulisher
Apr 23, 2025

Major Breakthrough: Silexion's Multi-KRAS Cancer Drug Enters Manufacturing Phase with Industry Giant Catalent - Stock Titan

Apr 23, 2025
pulisher
Apr 05, 2025

Titan Pharmaceuticals (NASDAQ:TTNP) and Silexion Therapeutics (NASDAQ:SLXN) Head to Head Review - Defense World

Apr 05, 2025
pulisher
Mar 31, 2025

Silexion plans dual-route strategy for SIL-204 for KRAS-driven pancreatic cancer - BioWorld MedTech

Mar 31, 2025
pulisher
Mar 29, 2025

Buy Rating for Silexion Therapeutics Driven by Promising SIL-204 Developments and Market Expansion - TipRanks

Mar 29, 2025
pulisher
Mar 28, 2025

Silexion advances dual-route strategy for KRAS cancer therapy By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data - markets.businessinsider.com

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics Unveils Innovative Expanded - GlobeNewswire

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics announces expanded development plan for SIL204 - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics Expands SIL204 Development Plan - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion advances dual-route strategy for KRAS cancer therapy - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics Corp Unveils Expanded Development Plan For Sil204 - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Game-Changing Cancer Treatment: Silexion's New Dual-Action Drug Targets Both Primary Tumors and Metastases - Stock Titan

Mar 28, 2025
pulisher
Mar 23, 2025

Maxim Group Cuts Silexion Therapeutics (NASDAQ:SLXN) Price Target to $5.00 - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Silexion Therapeutics price target lowered to $5 from $9 at Maxim - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Silexion announces completion of expanded development plan for SIL204 - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Silexion Therapeutics Corp. Announces Expanded Development Plan for SIL204 at NeauxCancer 2025 Conference - Nasdaq

Mar 21, 2025
pulisher
Mar 21, 2025

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference - GlobeNewswire

Mar 21, 2025
pulisher
Mar 21, 2025

Revolutionary KRAS Cancer Treatment: Silexion Expands Development Strategy for SIL204 - StockTitan

Mar 21, 2025
pulisher
Mar 18, 2025

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

Silexion Therapeutics Corp. Reports 2024 Financial Results and Progress on SIL204 for KRAS-Driven Cancers - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Silexion Therapeutics Corp SEC 10-K Report - TradingView

Mar 18, 2025
pulisher
Mar 17, 2025

Revolutionary Cancer Drug SIL204 Tackles Both Primary Tumors and Metastasis with 80% Success Rate - StockTitan

Mar 17, 2025

Finanzdaten der Silexion Therapeutics Corp-Aktie (SLXN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.06
price up icon 0.95%
$31.31
price up icon 3.40%
$580.95
price up icon 0.82%
$292.90
price up icon 2.57%
$4.64
price up icon 6.67%
$77.49
price up icon 4.82%
Kapitalisierung:     |  Volumen (24h):